With box warnings

Without box warnings

Branded

Generic

4 results

cinqair
(Reslizumab)
Teva Respiratory, LLC
Usage: CINQAIR® is indicated as an add-on maintenance treatment for adults (18+) with severe asthma exhibiting an eosinophilic phenotype. It is not intended for other eosinophilic conditions or for acute bronchospasm relief or status asthmaticus.
fasenra
(Benralizumab)
AstraZeneca Pharmaceuticals LP
Usage: FASENRA is indicated for the add-on maintenance treatment of severe asthma in patients aged 6 years and older with an eosinophilic phenotype and for treating eosinophilic granulomatosis with polyangiitis (EGPA) in adults. It is not for acute bronchospasm relief.
nucala
(mepolizumab)
GlaxoSmithKline LLC
Usage: NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.
tezspire
(tezepelumab-ekko)
Amgen, Inc
Usage: TEZSPIRE is indicated as an add-on maintenance treatment for severe asthma in patients aged 12 years and older. It is not meant for immediate relief of acute bronchospasm or status asthmaticus.

Medications for Severe Asthma

cinqair